Table 1.
Baseline patient demographics and disease characteristics
| Characteristics | Patients who underwent surgery (n = 10) | Patients who did not undergo surgery (n = 53)* | p values |
|---|---|---|---|
| Sex (male/female), n | 10/0 | 46/7 | 0.352 |
| Median age, years (range) | 52 (44–72) | 57 (25–74) | 0.547 |
| ECOG performance status (0/1/2), n | 5/5/0 | 12/33/8 | 0.155 |
| Etiology of HCC (HBV/HCV/non-viral), n | 10/0/0 | 51/0/2 | 1.000 |
| BCLC stage (A/B/C), n | 1/2/7 | 1/13/39 | 0.466 |
| China liver cancer stage (Ib/IIa/IIb/IIIa/IIIb), n | 1/1/1/7/0 | 1/1/12/19/20 | 0.087 |
| Macrovascular invasion (yes/no), n | 7/3 | 27/26 | 0.319 |
| Portal vein tumor thrombus (Vp0/Vp1-2/Vp3/Vp4), n | 5/0/2/3 | 28/1/10/14 | 1.000 |
| Hepatic vein tumor thrombus (Vv0-1/ Vv2/Vv3), n | 8/1/1 | 46/1/6 | 0.538 |
| Extrahepatic disease (yes/no), n | 0/10 | 20/33 | 0.023 |
| Child-Pugh class (A/B), n | 10/0 | 50/3 | 1.000 |
| Baseline AFP, median (range), ng/mL | 1,122 (17.5–60,500) | 860 (1–60,500) | 0.807 |
| Baseline AFP ≥400 ng/mL, n (%) | 7 (70.0) | 32 (60.4) | 0.729 |
| Baseline PIVKA-II, median (range), mAU/mL | 3,927 (111–75,000) | 16,245 (43–75,000) | 0.194 |
| Baseline PIVKA-II ≥1,000 mAU/mL, n (%) | 8 (80.0) | 35 (66.0) | 0.481 |
ECOG, Eastern Cooperative Oncology Group; HCC, hepatocellular carcinoma; HBV, hepatitis B; HCV, hepatitis C; BCLC, Barcelona Clinic Liver Cancer; AFP, alpha-fetoprotein; PIVKA-II, protein induced by vitamin K absence-II.
*
Including 2 patients who met the criteria for R0 resection but not did not undergo surgery.